Jubilant Life Sciences hits rock bottom on USFDA warning letter for US facility

05 Dec 2013 Evaluate

Jubilant Life Sciences is currently trading at its lower circuit limit of Rs. 126.05, down by 13.95 points or 9.96% from its previous closing of Rs. 140.00 on the BSE.

The scrip opened at Rs. 143.50 and has touched a high and low of Rs. 145.80 and Rs. 126.05 respectively. So far 416302 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 248.25 on 10-Dec-2012 and a 52 week low of Rs. 65.10 on 28-Aug-2013.

Last one week high and low of the scrip stood at Rs. 150.00 and Rs. 125.00 respectively. The current market cap of the company is Rs. 2007.74 crore.

The promoters holding in the company stood at 53.95% while Institutions and Non-Institutions held 28.41% and 17.65% respectively.

Jubilant Life Sciences ’one of its manufacturing facilities, Jubilant HollisterStier, LLC (JHS) located at Spokane, Washington State, US has been issued a Warning Letter (WL) by US Food and Drug Administration (FDA).

As required by FDA, JHS-Spokane will respond to this WL on or before December 12, 2013. The response will identify corrective actions already been completed as well as some pending corrective actions to ensure on-going cGMP compliance.

FDA specified in the WL that until all corrections have been completed and that they have confirmed correction of the violations and firm compliance to cGMPs, FDA may withhold approval of new applications or supplements listing JHS-Spokane as the drug product manufacturer.

The company expects that the on-going manufacturing, distribution and sale of products from this facility will not be impacted as the WL will affect new approvals only. JHS-Spokane is committed to implementing the necessary corrective actions required to address the FDA concerns, and will work closely with the FDA to bring resolution to this matter.

During 1HFY14, the contract manufacturing operations at JHS-Spokane contributed 7% to consolidated sales and 4% to consolidated EBITDA of JLL.

Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. As on September 30, 2013, Jubilant Life Sciences had a total of 676 filings for formulations of which 218 have been approved in various regions of the world. This includes 58 ANDAs filed in the US and 48 Dossier filings in Europe.

 

Jubilant Pharmova Share Price

1046.55 -2.85 (-0.27%)
30-Dec-2025 14:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.00
Dr. Reddys Lab 1266.95
Cipla 1486.10
Zydus Lifesciences 901.30
Lupin 2085.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×